Send to

Choose Destination
Med Sci (Paris). 2018 Nov;34(11):929-935. doi: 10.1051/medsci/2018238. Epub 2018 Dec 10.

[Brain insulin signaling and Tau: impact for Alzheimer's disease and Tauopathies].

[Article in French]

Author information

Byrd Alzheimer's Institute, department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, États-Unis.
Centre de recherche du Centre hospitalier de l'université Laval de Québec, axe neurosciences, université Laval, Québec, QC, Canada.
Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, « Alzheimer & Tauopathies », LabEx DISTALZ, F-59000 Lille, France.


Alzheimer's disease (AD) is a neurodegenerative disease primarily characterized by cognitive deficits and neuropathological lesions such as Tau aggregates and amyloid plaques, but also associated with metabolic and neuroendocrine abnormalities, such as impairment of cerebral insulin. However, the origin of these symptoms and their relationship to pathology and cognitive disorders remain poorly understood. Insulin is a hormone involved in the control of peripheral and central energy homeostasis, and insulin-resistant state has been linked to increased risk of dementia. It is now well established that brain insulin resistance can exacerbate Tau lesions. Conversely, recent data indicate that Tau protein can modulate insulin signalling in the brain, creating a vicious circle precipitating the pathological AD. This review aims to highlight our current understanding of the role of insulin in the brain and its relationship with Tau protein in the context of AD and Tauopathies.


Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center